

Research Article

## Quaking Gene Expression as a Prognostic Marker in Neural Inflammation Disorders

Masoumeh Rostami <sup>1</sup> , Azam Mirarab <sup>2</sup> , Alireza Mohebbi <sup>3\*</sup> 

1. Department of Immunotherapy and Vaccine Research, Pasteur Institute of Iran, Tehran, Iran

2. Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

3. Vista Aria Rena Gene Inc., Golestan Province, Gorgan, Iran

\*Correspondence: Alireza Mohebbi, Golestan University of Medical Sciences, Gorgan, Iran

Email: Mohebbi-a@goums.ac.ir

Received February 26, 2022 Received in revised form April 10, 2022 Accepted May 10, 2022

### ABSTRACT

**Background and objectives:** Cancer stem cells (CSCs) may contribute to tumor initiation, distant metastasis, and chemo-resistance. Quaking (QKI) is a RNA binding protein, a tumor suppressor, and a well-known stem cell biomarker in central nervous system (CNS) cancer. The aim of this study was to identify the potential of QKI mRNA as a prognostic marker for CNS cancer.

**Methods:** The Cancer Genome Atlas (TCGA) was investigated for gene expression profile within CNS cancer data. Further analysis was done through cBioPortal and COSMIC to explore the QKI gene mutation(s). Moreover, QKI mRNA levels were evaluated by using SAGE Genie tools. The Kaplan-Meier Plotter was utilized to identify prognostic role of QKI mRNA levels in these cancers.

**Results:** Higher levels of QKI mRNA were detected in brain cancer tissues. Altered QKI gene expression was observed in 2% (56/2,958) of patients. Missense QKI gene mutation rate was 35.29%. The QKI gene alterations led to deleterious amino acid changes, including P181R, Q112P, and A220G. Altered QKI gene expression was significantly correlated with reduced survival rate ( $p < 0.05$ ).

**Conclusion:** The QKI gene is most expressed in brain tissues. In patients with gliomas, altered QKI expression/mutation is associated with a shorter survival rate. The findings of this study indicate that the QKI gene mutations can be considered as a potential prognostic biomarker for brain malignancies.

**Keywords:** Quaking; Biomarker; The Cancer Genome Atlas; neural inflammation disorders



DOI: 10.29252/Jcbr.6.2.1

**How to Cite:** Masoumeh Rostami, Azam Mirarab, Alireza Mohebbi. Quaking Gene Expression as a Prognostic Marker in Neural Inflammation Disorders. Journal of Clinical and Basic Research. 2022; 6 (2) :1-11

## INTRODUCTION

The extracellular matrix, mesenchymal stem cells, cancer-associated fibroblasts, endothelial cells, immune cells, and a complex network of cytokines and growth factors make up the tumor microenvironment (1). Tumor tissues are composed of a variety of cancer cells, including cancer stem cells (CSCs), which can differentiate into cancer cells (2,3). The stem cell niche is a milieu in which tissue-specific stem cells in normal organs maintain their stemness. The most common and deadly primary brain tumor is glioblastoma (GBM). Glioma stem cells are thought to have a role in tumors' resistance to standard therapy. These cells have distinct surface markers, control specific signaling pathways, and play an important role in the development of glioma vessels (4,5). Niches have been identified in multiple cancers, and they often assimilate the signals of niches for the tissues from which the CSCs appeared (6,8). However, it is not understood how these cells still manage to preserve their nature when they invade and migrate from their homes to other areas where ideal niches are less likely to be available (9).

Brain tumors and metastases represent a heterogeneous set of conditions (10). Primary brain tumors such as astrocytic tumors, oligodendrogliomas, ependymomas, and mixed gliomas are all referred to as gliomas (11). Adults' most usual lethal brain tumor is grade IV glioma also known as GBM, with over 10,000 cases diagnosed annually in the United States (12). Evidence shows that a population of GBM cells has a stable ability to self-renew and produce new tumors that keep the features of original tumors (13,14).

The ability of stem cells to invade and migrate raises the question of how these cells maintain their stemness when they

come into contact with varied ingredient compositions of a new microenvironment (15). Therefore, looking for genetic changes could help CSCs to keep stemness outside their niches (16). The Quaking gene (QKI), as a tumor suppressor gene, may potentially affect CSC stemness. The gene encodes QKI, a STAR-family RNA-binding protein that is involved in RNA homeostasis (19,20). The RNA-binding protein QKI is highly expressed in brain cells (17), and play a regulatory role in brain development via modulating the stability of mRNAs that promote differentiation and inhibiting cell cycle progress (18). In the present study, the significance of QKI mRNA in human central nervous system (CNS) cancer was evaluated by using the Cancer Genome Atlas (TCGA) data portals.


## MATERIALS AND METHODS

### Analysis for QKI mutations

The Catalog of Somatic Mutations in Cancer (COSMIC) database was used to analyze QKI mutations (21). Pie charts were generated for a distribution survey and substitutions on the coding strand in CNS cancer.

### CBioPortal analysis for alteration frequency of QKI

Alteration frequency of QKI mRNA was performed using cBioPortal for Cancer Genomics (22,23). All searches were performed according to the cBioPortal's online instructions. The database query was based on mutation and altered expression of the QKI in six CNS/brain studies (Brain Low Grade Glioma (TCGA, Firehose Legacy), Brain Low Grade Glioma (TCGA PanCancer Atlas), GBM (TCGA, Cell 2013), GBM (TCGA, Nature 2008), Low-Grade Gliomas (UCSF, Science 2014), Merged Cohort of LCG and GBM (TCGA, Cell 2016), including 3010 samples of 2958 patients (summarized in Figure 1). The overlapped studies were discarded.



**Figure 1. Summary of QKI gene alteration in glioma samples analyzed by cBioPortal**

### Serial analysis of gene expression (SAGE)

All available published SAGE data were used to analyze QKI expression in normal and cancerous tissues. Digital QKI gene expression profiles were analyzed using SAGE Genie tools (24).

### Kaplan-Meier plotter analysis

The prognostic value of the QKI gene in CNS cancer was analyzed using the Kaplan-Meier plotter (25) and PPISURV (26). Overall survival of the patient with high and low levels of QKI was shown by using a Kaplan-Meier survival plot.

## RESULTS

### QKI mutation in glioma

The information of mutations and mutation types were generated using cBioPortal. Mutation data for QKI were only provided in 17 patients (Table 1). Missense mutation rate was 35.29% (6/17). Furthermore, deletions resulting from frameshifts were observed in 29.41% (5/17) of mutant samples of glioma cancer. Missense mutations were

G163984476 in 50% (3/6), G163956153 in 33.33% (2/6), and C163899861 in 16.67% (1/6) of patients. Alteration frequency of QKI mutation in CNS cancer was analyzed by using cBioPortal. Moreover, 56 of 2,958 (2%) patients had altered QKI gene.

### QKI mRNA in Glioma cancer tissues


The expression profile of QKI was found by using the SAGE Digital Gene Expression Display. Higher levels of QKI mRNA were mainly in the brain, spinal cord, breast, stomach, skin, and muscle cancer tissues, compared with their matched normal tissues (Figure 2).

No correlation was observed between the QKI gene expression and its relative protein copy numbers in different types of QKI gene alterations (Figure 3), while the opposite role of QKI mRNA was observed in CNS cancer ( $p=0.005$ ). In addition, we analyzed the prognostic roles of QKI mRNA in subtypes of CNS cancer, and the results showed that QKI mRNA had no influence on mixed-type CNS cancer ( $p=0.14$ ).


**Table 1. Altered *QKI* gene information in 17 patients**

Sample ID	Cancer type	Cancer Type Detailed	Protein Change	Mutation Type	Copy	Variant Type	Sex
TCGA-28-5208-01	Glioma	Diffuse Glioma	V99Lfs*31	Frame_Shift_Del	DEL	Diploid	Male
TCGA-06-0650-01	Glioma	Diffuse Glioma	P181R	Missense_Mutation	SNP	Diploid	Female
TCGA-06-0155-01	Glioma	Diffuse Glioma	Q112P	Missense_Mutation	SNP	ShallowDel	Male
TCGA-28-5207-01	Glioma	Diffuse Glioma	R256Kfs*18	Frame_Shift_Del	DEL	DeepDel	Male
TCGA-06-0237-01	Glioma	Diffuse Glioma	X312_splice	Splice_Site	DEL	Gain	Female
TCGA-OX-A56R-01	Glioma	Diffuse Glioma	E174del	In_Frame_Del	DEL	ShallowDel	Male
TCGA-FG-5965-01	Glioma	Diffuse Glioma	A220G	Missense_Mutation	SNP	Diploid	Female
TCGA-FG-5965-01	Glioma	Oligoastrocytoma	A220G	Missense_Mutation	SNP	Diploid	Female
TCGA-FG-5965-01	Diffuse Glioma	Oligoastrocytoma	A220G	Missense_Mutation	SNP	Diploid	Female
TCGA-28-5208-01	Glioma	Glioblastoma Multiforme	V99Lfs*31	Frame_Shift_Del	DEL	Diploid	Male
TCGA-06-0650-01	Glioma	Glioblastoma Multiforme	P181R	Missense_Mutation	SNP	Diploid	Female
TCGA-28-5207-01	Glioma	Glioblastoma Multiforme	R256Kfs*18	Frame_Shift_Del	DEL	DeepDel	Male
TCGA-06-0237-01	Glioma	Glioblastoma Multiforme	X312_splice	Splice_Site	DEL	Gain	Female
TCGA-HT-7689-01	Diffuse Glioma	Oligodendroglioma	QKI-AKAP7	fusion	FUSION	ShallowDel	Female
TCGA-DU-6404-01	Diffuse Glioma	Oligodendroglioma	PACRG-QKI	fusion	FUSION	Diploid	Female
TCGA-HT-8114-01	Diffuse Glioma	Oligoastrocytoma	PACRG-QKI	fusion	FUSION	Diploid	Male
TCGA-WY-A859-01	Diffuse Glioma	Astrocytoma	NSD2-QKI	fusion	FUSION	Diploid	Female

**Data includes six duplicate mutations in patients with multiple samples**



**Figure 2.** The alteration frequencies of the *QKI* gene across different cancer studies. Expression of the *QKI* gene was highest in brain (GTEx portal) (38).




**Figure 3.** The mRNA expression of *QKI*

**Determination of QKI gene alterations across different cancers and overall survival rate**

The QKI gene alterations (including mutations) led to amino acid changes with deleterious impacts on protein function. These included P181R, Q112P, and A220G. The QKI mutations and deletions were less frequent than amplifications in cancer

patients. In addition, the QKI gene was notably amplified in several cancers, including stomach, skin, colon, and CNS cancers. In stomach cancer, QKI protein mutations were observed in 17 patients.

Further data showed significantly reduced overall survival rate of patients with altered QKI gene when compared to the unaltered group (Figure 4).



**Figure 4. Disease-free survival Kaplan-Meier estimate.** Data show that patients with altered QKI gene had less overall survival (~6 years) than those with unaltered QKI gene (p=0.0291)

**DISCUSSION**

The niche is unique where preserved stem cells are undifferentiated and circulated through self-renewal. As seen for somatic stem cells, many

studies have identified a niche for CSCs that are important for preserving their self-renewal and promoting tumorigenesis (6,8). However, these

seemingly specialized CSC niches are absent when CSCs invade other areas or tissues by various routes and metastasize to distant organs via circulation. This raises the question how CSCs keep their self-renewal power outside their niches. Shingu et al. showed that postnatal deletion of Pten and Trp53 could expand the neural stem cell (NSC) population in subventricular zones (SVZs). The lack of NSC self-renewal outside SVZs suggests the inability of NSCs to uphold self-renewal outside their niches, thereby preventing Pten<sup>-/-</sup>; Trp53<sup>-/-</sup> premalignant-NSCs from developing into gliomas. They also suggested that Qk deletion in Pten<sup>-/-</sup>; Trp53<sup>-/-</sup> premalignant-NSCs improved self-renewal, especially outside their niches, promoting gliomagenesis (3).

Previously, Zheng et al. showed that deletion of Pten and Trp53 in embryonic NSCs could raise sphere-forming capacity/stemness by upregulating Myc, leading to low-grade development and showing that embryonic development NSCs are more manageable to transform than postnatal NSCs (27). Nevertheless, in the model of Zheng et al. (with deletion of Pten and Trp53 in embryonic NSCs), GBM developed with a much more extended latency period (105 days versus 300 days) and

lower penetrance (92% versus 25%), suggesting that other genetic or epigenetic changes still must be gained to allow embryonic premalignant neural stem cells to preserve self-renewal outside their niches, to permit full progression of glioma.

The QKI gene has long been studied as a critical gene for oligodendrocyte differentiation and myelin formation (20,28). Other studies confirmed that QKI is needed for oligodendrocyte differentiation (3). This gene is also important for developing smooth muscle, endothelial cells, and monocytes or macrophages (20). In addition, QKI is expressed in NSCs and is a major regulator of self-renewal and differentiation. It has been shown that QKI may regulate RNA homeostasis, including RNA stability, splicing, translation, miRNA processing, and circular RNA biogenesis (19,21).

In support of the importance of QKI as a tumor suppressor, a previous analysis of the TCGA database of GBM demonstrated QKI as the sole gene within the small common region of the 6q26 deletions (32% deletion rate and 1.7% mutation rate) (3,29). Furthermore, QKI downregulation by methylation of the QKI locus (chromosome 6, base 163,755,107) was also

reported in 50 of 250 (20%) GBM samples (30). In angiocentric glioma, nearly 90% of tumors have an MYB-QKI translocation, which disrupts QKI (31,32). Other than in gliomas, QKI is a tumor suppressor in other malignancies, including gastric (33), breast (34), colon (35), prostate (36), and oral (37) cancers.

## CONCLUSION

Expression of the QKI gene is highest in the brain tissue. Altered QKI gene expression/mutation is correlated with short survival rates in patients with gliomas. The results of the present study suggest that the QKI gene alteration could be considered as a novel prognosis biomarker for CNS/brain cancers.

## ACKNOWLEDGMENTS

None.

## DECLARATIONS

### Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

### Ethics approvals and consent to participate

Not applicable.

## Conflict of interest

The authors declare that there is no conflict of interest regarding publication of this article.

## References

1. López de Andrés J, Griñán-Lisón C, Jiménez G, Marchal JA. Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. *Journal of hematology & oncology*. 2020 Dec;13(1):1-22. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[PMCID](#)] [[Google Scholar](#)]
2. Shenghui HE, Nakada D, Morrison SJ. Mechanisms of stem cell self-renewal. *Annual Review of Cell and Developmental*. 2009 Nov 10;25:377-406. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[Google Scholar](#)]
3. Shingu T, Ho AL, Yuan L, Zhou X, Dai C, Zheng S, Wang Q, Zhong Y, Chang Q, Horner JW, Liebelt BD. Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. *Nature genetics*. 2017 Jan;49(1):75-86. [[View at Publisher](#)] [[Google Scholar](#)]
4. Liebelt BD, Shingu T, Zhou X, Ren J, Shin SA, Hu J. Glioma stem cells: signaling, microenvironment, and therapy. *Stem cells international*. 2016 Oct;2016. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[PMCID](#)] [[Google Scholar](#)]
5. Alves AL, Gomes IN, Carloni AC, Rosa MN, da Silva LS, Evangelista AF, Reis RM, Silva VA. Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives. *Stem Cell Research & Therapy*. 2021 Dec;12(1):1-22.



[[View at Publisher](#)] [[DOI](#)] [[PMID](#)]  
[[PMCID](#)] [[Google Scholar](#)]

6. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A. A perivascular niche for brain tumor stem cells. *Cancer cell*. 2007 Jan 1;11(1):69-82. [[View at Publisher](#)] [[Google Scholar](#)]

7. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. *Cancer cell*. 2009 Jun 2;15(6):501-13. [[View at Publisher](#)] [[Google Scholar](#)]

8. Merlos-Suárez A, Barriga FM, Jung P, Iglesias M, Céspedes MV, Rossell D, Sevillano M, Hernando-Momblona X, da Silva-Diz V, Muñoz P, Clevers H. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. *Cell stem cell*. 2011 May 6;8(5):511-24. [[View at Publisher](#)] [[Google Scholar](#)]

9. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. *Cancer research*. 2006 May 1;66(9):4553-7. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[Google Scholar](#)]

10. Focusing on brain tumours and brain metastasis. *Nat Rev Cancer*. 2019 Dec ;20(1):1-1. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)]

11. Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. *Asian Pacific journal of cancer prevention: APJCP*. 2017;18(1):3. [[PubMed](#)] [[Google Scholar](#)]

12. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C. Emerging insights into the molecular and cellular basis of glioblastoma. *Genes & development*. 2012 Apr 15;26(8):756-84. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[PMCID](#)] [[Google Scholar](#)]

13. Rich JN, Eyler CE. Cancer stem cells in brain tumor biology. In *Cold Spring Harbor symposia on quantitative biology 2008 Jan 1 (Vol. 73, pp. 411-420)*. Cold Spring Harbor Laboratory Press. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[PMCID](#)] [[Google Scholar](#)]

14. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. *Nature Reviews Cancer*. 2006 Jun;6(6):425-36. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[Google Scholar](#)]

15. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. *Journal of clinical oncology*. 2003 Apr 15;21(8):1624-36. [[DOI](#)] [[PMID](#)] [[Google Scholar](#)]

16. Hu J, Ho AL, Yuan L, Hu B, Hua S, Hwang SS, Zhang J, Hu T, Zheng H, Gan B, Wu G. Neutralization of terminal differentiation in gliomagenesis. *Proceedings of the National Academy of Sciences*. 2013 Sep 3;110(36):14520-7. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[PMCID](#)] [[Google Scholar](#)]

17. Suiko T, Kobayashi K, Aono K, Kawashima T, Inoue K, Ku L, Feng Y, Koike C. Expression of quaking RNA-binding protein in the adult and developing mouse retina. *PLoS One*. 2016 May 19;11(5):e0156033. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[PMCID](#)] [[Google Scholar](#)]

18. Sakers K, Liu Y, Llaci L, Lee SM, Vasek MJ, Rieger MA, Brophy S, Tycksen E, Lewis R, Maloney SE, Dougherty JD. Loss of Quaking RNA binding protein disrupts the expression of genes associated with astrocyte maturation in mouse brain. *Nature communications*. 2021 Mar 9;12(1):1-4. [[View at Publisher](#)] [[Google Scholar](#)]
19. Chen AJ, Paik JH, Zhang H, Shukla SA, Mortensen R, Hu J, Ying H, Hu B, Hurt J, Farny N, Dong C. STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA. *Genes & development*. 2012 Jul 1;26(13):1459-72. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[PMCID](#)] [[Google Scholar](#)]
20. Darbelli L, Richard S. Emerging functions of the Quaking RNA-binding proteins and link to human diseases. *Wiley Interdisciplinary Reviews: RNA*. 2016 May;7(3):399-412. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[Google Scholar](#)]
21. Forbes S, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR. The catalogue of somatic mutations in cancer (COSMIC). *Current protocols in human genetics*. 2008 Apr;57(1):10-1. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[PMCID](#)] [[Google Scholar](#)]
22. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Science signaling*. 2013 Apr 2;6(269):pl1-. [[View at Publisher](#)] [[DOI](#)] [[Google Scholar](#)]
23. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer discovery*. 2012 May 1;2(5):401-4. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[PMCID](#)] [[Google Scholar](#)]
24. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. *Science*. 1995 Oct 20;270(5235):484-7. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[Google Scholar](#)]
25. Szász AM, Lánckzy A, Nagy Á, Förster S, Hark K, Green JE, Boussioutas A, Busuttill R, Szabó A, Györfly B. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. *Oncotarget*. 2016 Aug 2;7(31):49322. [[DOI](#)] [[PMID](#)] [[PMCID](#)] [[Google Scholar](#)]
26. Antonov AV, Krestyaninova M, Knight RA, Rodchenkov I, Melino G, Barlev NA. PPISURV: a novel bioinformatics tool for uncovering the hidden role of specific genes in cancer survival outcome. *Oncogene*. 2014 Mar;33(13):1621-8. [[View at Publisher](#)] [[Google Scholar](#)]
27. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. *Nature*. 2008 Oct;455(7216):1129-33. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[PMCID](#)] [[Google Scholar](#)]
28. Chénard CA, Richard S. New implications for the QUAKING RNA binding protein in human disease. *Journal of neuroscience research*. 2008 Feb 1;86(2):233-42. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[Google Scholar](#)]
29. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR,

Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhi R. The somatic genomic landscape of glioblastoma. *Cell*. 2014 Apr 24;157(3):753. [[Google Scholar](#)]

30. Fuchs E, Tumber T, Guasch G. Socializing with the neighbors: stem cells and their niche. *Cell*. 2004 Mar 19;116(6):769-78. [[View at Publisher](#)] [[Google Scholar](#)]

31. Qaddoumi I, Orisme W, Wen J, Santiago T, Gupta K, Dalton JD, Tang B, Hauptfear K, Punchihewa C, Easton J, Mulder H. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. *Acta neuropathologica*. 2016 Jun;131(6):833-45. [[View at Publisher](#)] [[Google Scholar](#)]

32. Bandopadhyay P, Ramkissoon LA, Jain P, Bergthold G, Wala J, Zeid R, et al. MYB-QKI rearrangements in angiogenic glioma drive tumorigenicity through a tripartite mechanism. *Nat Genet*. 2016 Feb; 48(3):273-82 [[View at Publisher](#)]

33. Bian Y, Wang L, Lu H, Yang G, Zhang Z, Fu H, Lu X, Wei M, Sun J, Zhao Q, Dong G. Downregulation of tumor suppressor QKI in gastric cancer and its implication in cancer prognosis. *Biochemical and biophysical research communications*. 2012 May 25;422(1):187-93. [[View at Publisher](#)] [[Google Scholar](#)]

34. Yu F, Jin L, Yang G, Ji L, Wang F, Lu Z. Post-transcriptional repression of FOXO1

by QKI results in low levels of FOXO1 expression in breast cancer cells. *Oncology reports*. 2014 Mar 1;31(3):1459-65. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[Google Scholar](#)]

35. Yang G, Fu H, Zhang J, Lu X, Yu F, Jin L, Bai L, Huang B, Shen L, Feng Y, Yao L. RNA-binding protein quaking, a critical regulator of colon epithelial differentiation and a suppressor of colon cancer. *Gastroenterology*. 2010 Jan 1;138(1):231-40. [[View at Publisher](#)] [[Google Scholar](#)]

36. Zhao YI, Zhang G, Wei M, Lu X, Fu H, Feng F, Wang S, Lu W, Wu N, Lu Z, Yuan J. The tumor suppressing effects of QKI-5 in prostate cancer: a novel diagnostic and prognostic protein. *Cancer biology & therapy*. 2014 Jan 1;15(1):108-18. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[PMCID](#)] [[Google Scholar](#)]

37. Lu W, Feng F, Xu J, Lu X, Wang S, Wang L, Lu H, Wei M, Yang G, Wang L, Lu Z. QKI impairs self-renewal and tumorigenicity of oral cancer cells via repression of SOX2. *Cancer biology & therapy*. 2014 Sep 1;15(9):1174-84. [[View at Publisher](#)] [[DOI](#)] [[PMID](#)] [[PMCID](#)] [[Google Scholar](#)]

38. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, Hasz R, Walters G, Garcia F, Young N, Foster B. The genotype-tissue expression (GTEx) project. *Nature genetics*. 2013 Jun;45(6):580-5. [[View at Publisher](#)] [[Google Scholar](#)]